[PSA] gastric emptying is not what most of this community thinks it is
Short public-service post: gastric emptying is not what most of this community thinks it is.
GLP-1 receptor agonism acts both peripherally — insulin secretion in a glucose-dependent way, slowed gastric emptying — and centrally, on appetite regulation. The central component is the better explanation for sustained intake reduction.
Why mechanism talk keeps misleading people, including me.
A mechanism tells you a direction. It does not tell you a magnitude, a timescale, or whether the pathway is operative at the exposures involved. "Receptor X is expressed in tissue Y" is a fact; "therefore effect Z in a person" is a hypothesis with several missing steps.
The corrective is boring and it works: ask whether the evidence is preclinical or human, ask what exposure was used, and read the limitations section before the abstract. Most of the confidently wrong posts on this board — several of them mine — skipped all three.
The GIP question, which is the most interesting unsettled thing in this field.
Dual agonism at GIP and GLP-1 receptors produces clinical results that are robust and well replicated. What is not settled is the mechanism by which the GIP arm contributes — there is a genuine scientific argument about agonism versus antagonism at that receptor, with reasonable people and real data on both sides.
It is worth sitting with that. The clinical effect is not in doubt; the explanation is. That is an ordinary state of affairs in pharmacology and it is a good corrective to the confident mechanistic stories that circulate here.
Please do not ask me what dose you should be on. I genuinely do not know and neither does anyone else here.
best — the order this archive was captured in
Glucose-dependent insulin secretion is why hypoglycaemia risk is low as monotherapy: the effect scales with glycaemia rather than acting unconditionally.
Spent an evening on the receptor distribution literature and the side-effect map suddenly stopped looking random.
The incretin effect is the observation that oral glucose provokes a larger insulin response than intravenous glucose at matched glycaemia, and the difference is mediated by gut hormones. That is the foundation the whole class sits on.
This. Albumin binding and modification are why the half-life is what it is, and it is a design decision rather than an accident.
The mental model, in four steps, that makes the rest of this site legible.
One: gut hormones amplify the insulin response to food. Two: agonists at those receptors act peripherally on insulin secretion and gastric emptying, and centrally on appetite. Three: structural modification gives them a long half-life, so exposure is smooth and weekly. Four: tolerance develops to some effects and not to others.
From those four, most of what the experience boards report falls out: why the side effects cluster early, why they settle at a stable dose, why appetite reduction persists, and why the scale and the appetite move on different clocks.
The half-life explanation was the thing that made weekly dosing intuitive for me rather than arbitrary.
tolerance to the gastric effect develops, appetite effect largely persists
What was the exposure in that experiment relative to therapeutic?
Tried to build a mental model from mechanism alone and produced a confident prediction that the trial data flatly contradicted.
Is that from a human study or a preclinical model?
GIP receptor biology is genuinely unsettled — there is a live argument about agonism versus antagonism at the receptor — and the clinical results are robust regardless, which is an uncomfortable and interesting position.
That study was in a rodent model. Worth stating, since the thread has been reading it as human data.
Was completely wrong about the gastric emptying story in a thread here two years ago. Someone corrected me with a citation and I have not made that mistake since.
Disagree. That is a preclinical finding in a rodent model and you are stating it as human pharmacology.
Disagree.
Disagreeing with this specific inference — that is a preclinical result being read as human pharmacology.
a mechanism you can state is not a mechanism you have demonstrated
albumin binding is most of the half-life story
Tolerance to the gastric effect develops with continued exposure while the appetite effect largely persists. That single fact explains most of the "it settles but it still works" pattern the side-effect board reports.
the central appetite effect is doing more work than the gut effect
GIP is the arm people argue about because the biology is genuinely unsettled
Asked a question here that I thought was stupid and got three papers back. Best thread I have been in on this site.
Cosigning on GIP. The genuinely interesting thing is that the biology is not settled and the clinical result is nonetheless robust.
Correction: that is glucose-dependent insulin secretion, which is why hypoglycaemia risk is low as monotherapy. Not the same claim as you made.
Started reading limitations sections first. It has changed how much weight I give to almost everything posted here.
Yes. The discussion section is where the authors say what they actually think, and almost nobody here reads it.
receptor agonism is not the same as receptor activation in every tissue
receptor agonism is not the same as receptor activation in every tissue
lina_ndiaye is right that mechanism gives direction and not magnitude. Worth pinning.
Same view. Tolerance developing to the gastric effect while the appetite effect persists explains most of what the side-effect board reports.
receptor distribution is why the side effects are where they are
- 1Was completely wrong about the gastric emptying story in a thread here two…11 comments in this branch · started by u/rina_bergstrom
- 2Started reading limitations sections first. It has changed how much weight I…6 comments in this branch · started by u/slow_logbook